Market Cap | 1.21B | P/E | - | EPS this Y | 325.00% | Ern Qtrly Grth | - |
Income | 11.74M | Forward P/E | 30.60 | EPS next Y | 88.90% | 50D Avg Chg | 7.00% |
Sales | 248.37M | PEG | 1.96 | EPS past 5Y | - | 200D Avg Chg | 4.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | 35.60% | 52W High Chg | -20.00% |
Recommedations | 1.80 | Quick Ratio | 3.47 | Shares Outstanding | 275M | 52W Low Chg | 58.00% |
Insider Own | 1.86% | ROA | 7.44% | Shares Float | 268.88M | Beta | 1.31 |
Inst Own | 50.88% | ROE | - | Shares Shorted/Prior | 42.14M/38.83M | Price | 4.59 |
Gross Margin | 71.30% | Profit Margin | 4.73% | Avg. Volume | 2,709,170 | Target Price | 7.80 |
Oper. Margin | 22.22% | Earnings Date | Nov 5 | Volume | 2,813,672 | Change | 2.23% |
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Castagna Michael | Chief Executive Offi.. Chief Executive Officer | Dec 14 | Sell | 4 | 200,482 | 801,928 | 2,148,665 | 12/15/23 |
Castagna Michael | Chief Executive Offi.. Chief Executive Officer | Nov 01 | Sell | 4.25 | 10,000 | 42,500 | 2,349,147 | 11/02/23 |
Castagna Michael | Chief Executive Offi.. Chief Executive Officer | Oct 02 | Sell | 4.08 | 10,000 | 40,800 | 2,359,147 | 10/03/23 |
Castagna Michael | Chief Executive Offi.. Chief Executive Officer | Sep 01 | Sell | 4.61 | 10,000 | 46,100 | 2,436,039 | 09/05/23 |
Thomson David | EVP Genl Counsel & S.. EVP Genl Counsel & Secretary | Aug 27 | Sell | 4.78 | 8,100 | 38,718 | 798,835 | 08/28/23 |
Castagna Michael | Chief Executive Offi.. Chief Executive Officer | Aug 01 | Sell | 4.5686 | 10,000 | 45,686 | 2,496,735 | 08/01/23 |
Castagna Michael | Chief Executive Offi.. Chief Executive Officer | Jul 03 | Sell | 4.04 | 10,000 | 40,400 | 2,506,735 | 07/07/23 |
Castagna Michael | Chief Executive Offi.. Chief Executive Officer | Jun 01 | Sell | 4.5302 | 10,000 | 45,302 | 2,516,735 | 06/02/23 |
Castagna Michael | Chief Executive Offi.. Chief Executive Officer | May 25 | Sell | 4.55 | 150,000 | 682,500 | 2,526,735 | 05/26/23 |
Thomson David | EVP Genl Counsel & S.. EVP Genl Counsel & Secretary | May 22 | Sell | 4.68 | 95,576 | 447,296 | 735,263 | 05/24/23 |
Castagna Michael | Chief Executive Offi.. Chief Executive Officer | May 22 | Sell | 4.69 | 150,000 | 703,500 | 2,331,735 | 05/24/23 |
Binder Steven B. | Chief Financial Offi.. Chief Financial Officer | May 22 | Sell | 4.68 | 47,810 | 223,751 | 838,324 | 05/24/23 |
Castagna Michael | Chief Executive Offi.. Chief Executive Officer | May 05 | Sell | 4.00 | 10,000 | 40,000 | 2,020,128 | 05/05/23 |
Castagna Michael | Chief Executive Offi.. Chief Executive Officer | Apr 03 | Sell | 4.1287 | 10,000 | 41,287 | 2,030,128 | 04/05/23 |
Castagna Michael | Chief Executive Offi.. Chief Executive Officer | Mar 01 | Sell | 5.2748 | 10,000 | 52,748 | 2,040,128 | 03/03/23 |
Thomson David | EVP Genl Counsel & S.. EVP Genl Counsel & Secretary | Aug 27 | Sell | 3.67 | 7,000 | 25,690 | 726,035 | 08/29/22 |
Galindo Alejandro | EVP Endocrine Busine.. EVP Endocrine Business Unit | Aug 22 | Sell | 3.85 | 4,615 | 17,768 | 777,075 | 08/23/22 |
Binder Steven B. | Chief Financial Offi.. Chief Financial Officer | Jul 31 | Buy | 2.93 | 791 | 2,318 | 728,997 | 08/01/22 |
Castagna Michael | Chief Executive Offi.. Chief Executive Officer | Jul 31 | Buy | 2.93 | 3,147 | 9,221 | 2,084,486 | 08/01/22 |
Tross Stuart A | Chief People & Workp.. Chief People & Workpl Officer | Jul 31 | Buy | 2.93 | 4,581 | 13,422 | 830,650 | 08/01/22 |
Galindo Alejandro | EVP Endocrine Busine.. EVP Endocrine Business Unit | Jul 31 | Buy | 2.93 | 5,000 | 14,650 | 781,690 | 08/01/22 |
HOOPER ANTHONY C | Director Director | Feb 28 | Buy | 2.71 | 40,000 | 108,400 | 338,394 | 03/01/22 |
MUNDKUR CHRISTINE | Director Director | Feb 28 | Buy | 2.71 | 27,675 | 74,999 | 254,493 | 03/01/22 |
Galindo Alejandro | Chief Commercial Off.. Chief Commercial Officer | Jan 31 | Buy | 3.17 | 1,804 | 5,719 | 539,790 | 02/09/22 |
Castagna Michael | Chief Executive Offi.. Chief Executive Officer | Jan 31 | Buy | 3.17 | 1,804 | 5,719 | 1,505,098 | 02/09/22 |
Tross Stuart A | Chief People & Workp.. Chief People & Workpl Officer | Jan 31 | Buy | 3.17 | 2,254 | 7,145 | 622,785 | 02/09/22 |
Binder Steven B. | Chief Financial Offi.. Chief Financial Officer | Jan 31 | Buy | 3.17 | 711 | 2,254 | 534,178 | 02/02/22 |
Thomson David | EVP Genl Counsel & S.. EVP Genl Counsel & Secretary | Aug 27 | Sell | 4.64 | 4,100 | 19,024 | 567,391 | 08/27/21 |